Blog Inactive

Thank you for visiting my blog, but I am no longer keeping it current.

Zydelig approved for CLL and SLL

Zydelig (idelalisib) has been approved in combination with Rituxan for the treatment of relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in patients who have had at least two prior systemic therapies.

Belinostat for T-cell lymphoma

Belinostat (Beleodaq) has now been approved for relapsed or refractory T-cell lymphoma.

Zykadia for ALK+ tumors

Zykadia (ceritinib) is now approved for the treatment of metastatic ALK+ non-small cell lung cancer if there has been disease progression on crizotinib or the patient is intolerant to crizotinib.

New treatment for gastric cancer

Ramucirumab (Cyramza) has been approved for the treatment of advanced or metastatic gastric cancer and cancer of the GE junction with disease progression on or after prior treatment with certain types of chemotherapy.

Ibrutinib for CLL

Ibrutinib (Imbruvica) has now been FDA approved for the treatment of chronic lymphocytic leukemia in patients who have had at least one prior therapy.

New combination for melanoma

The FDA has approved the combination of trametinib (Mekinist) and dabrafenib (Tafinlar) for the treatment of unresectable malignant melanoma and metastatic melanoma with BRAF V600E or V600K mutations.